SEER Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Seer, Inc.

Nature Genetics Study Validates Seer’s Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers

4 days ago - By: Seer, Inc.

Nature Genetics Study Validates Seer’s Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers

a month ago - By: Seer, Inc.

Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025

a month ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

4 months ago - By: Benzinga - Mentions: OEC VTLE DIN INSE ...

Earnings Scheduled For August 6, 2025

a month ago - By: Seer, Inc.

Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025

a month ago - By: Seer, Inc.

Seer Reports Third Quarter 2025 Financial Results

a month ago - By: Seer, Inc.

Seer Reports Third Quarter 2025 Financial Results

a month ago - By: Seer, Inc.

Seer to Participate in Upcoming November Investor Conferences

a month ago - By: Seer, Inc.

Seer to Participate in Upcoming November Investor Conferences

2 months ago - By: Seer, Inc.

Seer to Report Third Quarter 2025 Financial Results on November 6, 2025

2 months ago - By: Seer, Inc.

Seer to Report Third Quarter 2025 Financial Results on November 6, 2025

2 months ago - By: RetinalGeniX Technologies, Inc. - Mentions: RTGN

RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases

2 months ago - By: Seer, Inc.

Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025

2 months ago - By: Seer, Inc.

Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025

3 months ago - By: Seer, Inc. - Mentions: WGS

Seer Appoints Isaac Ro to its Board of Directors

3 months ago - By: Seer, Inc.

Seer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

3 months ago - By: Seer, Inc.

Seer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

4 months ago - By: The Motley Fool

Seer (SEER) Q2 Revenue Jumps 32%

4 months ago - By: Zacks Investment Research - Mentions: DNTH

Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates

4 months ago - By: The Motley Fool

Seer (SEER) Q2 2025 Earnings Call Transcript

4 months ago - By: Seer, Inc.

Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

4 months ago - By: Seer, Inc.

Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

4 months ago - By: Seer, Inc.

Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference

4 months ago - By: Seer, Inc.

Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference

5 months ago - By: Seer, Inc.

Seer to Report Second Quarter 2025 Financial Results on August 6, 2025

5 months ago - By: Seer, Inc.

Seer to Report Second Quarter 2025 Financial Results on August 6, 2025

6 months ago - By: Seer, Inc.

Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

6 months ago - By: Seer, Inc.

Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

6 months ago - By: Seer, Inc.

Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency

6 months ago - By: Seer, Inc.

Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency

7 months ago - By: Seer, Inc.

Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

7 months ago - By: Seer, Inc.

Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

7 months ago - By: Zacks Investment Research - Mentions: CTMX

CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates

7 months ago - By: Zacks Investment Research - Mentions: RPRX

Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates

7 months ago - By: Zacks Investment Research - Mentions: ANAB

SEER INC (SEER) Stock News

SEER Latest News, Press Relases and Analysis

Nature Genetics Study Validates Seer’s Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers

Nature Genetics Study Validates Seer’s Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers

Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025

Earnings Scheduled For November 6, 2025

Earnings Scheduled For August 6, 2025

Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025

Seer Reports Third Quarter 2025 Financial Results

Seer Reports Third Quarter 2025 Financial Results

Seer to Participate in Upcoming November Investor Conferences

Seer to Participate in Upcoming November Investor Conferences

Seer to Report Third Quarter 2025 Financial Results on November 6, 2025

Seer to Report Third Quarter 2025 Financial Results on November 6, 2025

RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases

Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025

Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025

Seer Appoints Isaac Ro to its Board of Directors

Seer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Seer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Seer (SEER) Q2 Revenue Jumps 32%

Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates

Seer (SEER) Q2 2025 Earnings Call Transcript

Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference

Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference

Seer to Report Second Quarter 2025 Financial Results on August 6, 2025

Seer to Report Second Quarter 2025 Financial Results on August 6, 2025

Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency

Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency

Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates

Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates